ArticleScientific reports2025
Assessment of Opuntia ficus-indica supplementation on enhancing antioxidant levels.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Functional Foods and Micro- and Nanoplastics: Advances in Precision Nutritional Medicine for Oral-Gut-Brain Axis Health.Antioxidants (Basel, Switzerland) · 2026Review
- Shielding Human Adipocytes From Inflammation: The Protective Potential of Polyphenol-Rich Opuntia ficus-indica Cladode Extract.Molecular nutrition & food research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Opuntia ficus-indica (OFi) is a major fruit source prevalent in semiarid and arid regions across various countries worldwide. It is widely recognised for its potential health benefits; however, most studies investigating its effects have been limited to pre-clinical models, highlighting the need for further validation through clinical trials. This study aimed to evaluate the effectiveness of OFi supplementation in enhancing antioxidant levels. Fifty healthy participants, aged 18 years and older, including males and females, received a daily OFi supplement of 1500 mg for 3 months. These findings revealed a significant 48.1% increase in salivary total antioxidant capacity (TAC) (P < 0.001), indicating improved antioxidant activity. Simultaneously, oxidative stress biomarkers showed substantial reductions: malondialdehyde (MDA) decreased by 28.3%, nitrotyrosine (3-NT) decreased by 51.5%, and 8-hydroxy-2'-deoxyguanosine (8-OHdG) decreased by 59.8% (P < 0.001). Furthermore, participants reported a 20.1% improvement (P < 0.001) in Visual Analogue Scales (VAS), reflecting a notable enhancement in overall well-being. In conclusion, OFi exhibited promising efficacy in elevating antioxidant levels and mitigating oxidative stress. These findings suggest its potential as an adjuvant therapy for managing chronic conditions associated with oxidative stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.